Ascendis Pharma A/S (ASND) Raised to Strong-Buy at BidaskClub

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

A number of other research firms also recently commented on ASND. HC Wainwright reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, January 19th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $60.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, January 17th. Zacks Investment Research downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Bank of America raised their price target on Ascendis Pharma A/S from $36.00 to $46.00 in a report on Thursday, September 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $43.29.

Ascendis Pharma A/S (NASDAQ ASND) traded up $2.16 during trading hours on Thursday, reaching $53.64. The company’s stock had a trading volume of 207,639 shares, compared to its average volume of 169,854. Ascendis Pharma A/S has a 52 week low of $19.95 and a 52 week high of $55.00. The company has a market cap of $2,030.00 and a P/E ratio of -13.11.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, November 16th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.37). Ascendis Pharma A/S had a negative return on equity of 64.10% and a negative net margin of 4,687.42%. equities research analysts expect that Ascendis Pharma A/S will post -3.88 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. lifted its holdings in shares of Ascendis Pharma A/S by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 31,929 shares of the biotechnology company’s stock worth $1,157,000 after purchasing an additional 2,665 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of Ascendis Pharma A/S by 26.8% in the 3rd quarter. California Public Employees Retirement System now owns 19,658 shares of the biotechnology company’s stock worth $713,000 after purchasing an additional 4,158 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $194,000. Aperio Group LLC bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $241,000. Finally, Jane Street Group LLC bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $352,000. 78.93% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/28/ascendis-pharma-a-s-asnd-raised-to-strong-buy-at-bidaskclub.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply